Rapid Novor is a specialist in antibody characterization and discovery. Antibodies are a diverse class of peptides that can be used in various therapeutic applications. Rapid Novor is using their next generation protein sequencing technology to extract the full potential of antibodies. This includes their REmAb platform, that can sequence monoclonal antibodies from small protein samples and their HDX-MS epitope mapping platform, that employs mass-spectrometry to identify the binding site of an antibody to its corresponding antigen. Through these groundbreaking software, technology and method advances, Rapid Novor is facilitating drug discovery from cancer to immunity.

Rapid Novor

Founded: 2015
Location: Kitchener, ON
Employee range: 50 - 200
Funding: $120M May 2020

Short description:

Drug notes:

Long description:

Jobs: